This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07265752

/ Not yet recruitingPhase 2IIT

Tirzepatide for the Treatment of Cannabis Use Disorder: A Pilot Double-blind, Placebo-controlled, Crossover Trial

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Start Date01 Jul 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT07179120

/ Not yet recruitingPhase 2IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

1,314

Literatures (Medical) associated with Tirzepatide

01 Feb 2026·TISSUE & CELL

Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model

Article

Author: Marinho, Thatiany S ; Aguila, Marcia B ; Marcondes-de-Castro, Ilitch A ; Mandarim-de-Lacerda, Carlos A

The effects on hepatic mitochondrial structure, mitophagy, and cellular homeostasis were investigated when treated with Tirzepatide (Tzp), a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and menopause-conditions that collectively exacerbate metabolic dysfunction-associated steatotic liver disease (MASLD). Female C57BL/6 mice were fed either a control or high-fat, high-sucrose diet for 12 weeks, and half underwent bilateral ovariectomy to simulate menopause. Tzp was administered daily for four weeks. Liver tissue was evaluated for ultrastructural alterations, gene expression, and protein profiles. Untreated obese-diabetic and obese-diabetic-ovariectomized mice exhibited hepatocellular fat accumulation, mitochondrial swelling, and disorganized cristae, indicative of metabolic and oxidative stress. In contrast, Tzp-treated mice displayed preserved hepatic architecture and intact mitochondrial morphology. Tzp significantly downregulated autophagy genes (Ulk3, Atg5, Atg7) and key mitophagy regulators (PINK1, PRKN), reestablishing mitochondrial balance, primarily through the modulation of mitophagy and enhanced organelle stability. Simultaneously, it upregulated mitochondrial biogenesis markers (Ppargc1a, Tfam), antioxidant enzymes (SOD2, GR, GPX, CAT), and redox modulators (Sirt3, Nrf2), while normalizing oxidative stress-related genes (Nos1, Nox1). Tzp also mitigated endoplasmic reticulum (ER) stress by downregulating Atf4, Ddit3, and Gadd45 and rebalanced mitochondrial dynamics through the suppression of fission markers (Dnml1, Fis1) and the restoration of fusion mediators (Mfn1, Mfn2). Three-way ANOVA confirmed Tzp's broad regulatory effects on hepatic gene expression, while principal component analysis revealed clear transcriptional separation between treated and untreated groups. In conclusion, these findings demonstrate that Tzp preserves liver ultrastructure and restores mitochondrial dynamics, supporting its therapeutic potential in MASLD and hormone-related metabolic disorders.

01 Jan 2026·METABOLISM-CLINICAL AND EXPERIMENTAL

A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity

Article

Author: Roth, Christian L ; Chichura, Kylie S ; Doyle, Robert P ; den Hartigh, Laura J ; Ashlaw, Emily F ; Liu, Yongjun ; Mullins, Ginger ; Chepurny, Oleg G ; Holz, George G ; Elfers, Clinton T ; McGivney, Aelish ; Miranda, Isabella Chavez

Obesity and its sequelae cause significant morbidity and mortality worldwide. Current glucagon-like peptide-1 (GLP-1) receptor agonist-based treatments have significant side-effects associated with high rates of treatment discontinuation. Such concerns are greater still in children and adolescents. Thus, there remains a clinical unmet need to develop obesity and/or T2D mellitus therapies with significantly improved tolerability. Herein, we examined a polypharmacy approach combining melanocortin (MC) 4-, and GLP-1-receptor agonism in a single monomeric peptide based on α-MSH and Exendin-4 to bind and stimulate different peptide receptors in vitro, and to drive reductions in body weight and food intake in up to 7 weeks of treatment in comparison to semaglutide and tirzepatide as standard of care positive controls in diet-induced obese rats. Despite the monomeric peptide GLP-1-/MC4-receptor multiple agonist (KCEM1) being a non-lipidated, weaker GLP-1R agonist compared to semaglutide and tirzepatide, reductions in calorie intake and body weight were similar in all three groups after daily subcutaneous injections of the three peptides. In addition, KCEM1 offered superior glycemic control during glucose tolerance testing. In gene expression analyses, KCEM1, but not semaglutide or tirzepatide, significantly increased expression of glucose transporter 4 (GLUT4) and key glycolysis enzyme Pgk1 in skeletal muscle, while it reduced genetic markers of inflammation in different tissues, including inflammatory markers IL-6 and TNF-α in liver tissue. Furthermore, KCEM1 lowered hepatic lipid content and improved metabolic dysfunction-associated steatohepatitis (MASH) scoring. Overall, these data extend emerging concepts around the use of multi-receptor polypharmacy to treat metabolic syndrome.

01 Jan 2026·Methods in molecular biology (Clifton, N.J.)

Assessing the Role of PPKs in Phosphorylating Phytochrome A Using the Protoplast Transient Expression System

Article

Author: Feng, Ziyi ; Li, Jigang

Phytochrome A (phyA) is the far-red (FR) light photoreceptor in plants, and its phosphorylation status plays a critical role in modulating its protein activity and function. The protoplast transient expression system has become an increasingly efficient approach for analyzing promoter activities, protein subcellular localization, protein-protein interactions, etc. Recently, we employed the protoplast transient expression system to assess the role of the protein kinases PHOTOREGULATORY PROTEIN KINASES (PPKs) in phosphorylating phyA. TANDEM ZINC-FINGER/PLUS3 (TZP), a phyA-interacting protein previously shown to mediate phyA phosphorylation in vivo, was coexpressed with phyA and PPKs in Arabidopsis protoplasts. After the treatment with FR light, we observed that PPKs can directly phosphorylate phyA and that TZP enhances PPKs-mediated phosphorylation of phyA in Arabidopsis protoplasts. In this chapter, we will describe the detailed experimental procedures and the key points for implementing this system. This system may also be feasible for validating the relationship between other kinases and their potential substrates.

1,580

News (Medical) associated with Tirzepatide

27 Dec 2025

·pharma.economictimes.indiatimes.com

Pharma Sector 2025 Recap: A rewritten playbook and the shift to new league of Drugs

New Delhi: For the Indian pharmaceutical industry , 2025 marked a decisive shift as companies began positioning themselves to capitalise on the looming global patent cliff , increasingly looking beyond the traditional generics play. With a $250 billion opportunity on the horizon, drugmakers signalled strong intent in the booming GLP-1 space, besides joining the biosimilars bandwagon with strategic initiatives to expand and consolidate their presence in the coming years. “The year 2025 has been significant as the sector witnessed several novel launches, collaborations, digital progression and structural reforms,” Satish Reddy, Chairman of Dr. Reddy’s Laboratories Limited said. Speaking for Indian Pharma majors, Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA) added that, 2025 has been an inflection point for Indian pharma, signalling the country’s push to move up the value chain. Experts suggest the longstanding capital constraints and undervaluation challenges seem to be addressed with the timely introduction of research assistance under the Promotion of Research and Innovation Programme (PRIP), along with a $12 billion R&D fund—that provides critical support to incentivise innovation and prioritise calculated risk-taking. The rollout of PRIP has received a strong response from the industry, Jain said, noting that, “encouraging signals of shift towards innovation can be seen with leading Indian pharma companies acquiring higher-value products, closing licensing deals, and securing regulatory approvals for next-generation drugs.” While policies to support R&D are a step in the right direction, Reddy added that, “further impetus in making risk capital more accessible, can enable India to move from being the pharmacy to becoming the world’s hub for pharmaceutical innovation.” Obesity booster Among the impending patent cliffs, one of the most closely watched is of Novo Nordisk’s Semaglutid, --a GLP-1 receptor agonist for type-2 diabetes and weight management--whose market has expanded nearly tenfold over the past four years and received a further boost in recent months with the entry of global blockbuster brands such as Mounjaro (Tirzepatide) and Wegovy (Semaglutide). Taking a head start, companies like Cipla, Emcure have teamed with innovators, (Eli Lilly and Novo Nordisk respectively) for Tier-2, 3 markets, betting on the early-mover strategy to onboard maximum patients before the generics deluge. While as many as 20 companies are working on compounded versions, top regulatory officials expect , “7–10” marketers to introduce their branded formulations in the first phase, beginning March 2026. Meanwhile, alongside India, the segment also holds strong commercial potential across geographies with projections indicating a swift trajectory of touching $100 billion by 2030. Trade and Tariffs Amid the uncertainties stemming from the new US administration, the industry’s small-molecule stronghold remained a key growth driver, with exports climbing to over $30 billion supporting a balanced and positive outlook for the years ahead. “Pharma exports demonstrated strong resilience and as several blockbuster drugs lose patent protection, this development is expected to unlock significant growth prospects in global generics and speciality segments over the next few years,” Bhavin Mehta, Vice Chairman, Pharmexcil and Whole-Time Director, Kilitch Drugs said. Even as the trade deal with the US remains a key focus area, the successful closure of free trade agreement (FTA) with the UK, and favorable engagements with the EU helped to maintain a stable near-term outlook, and recent agreements involving Oman and New Zealand offer new export markets for the industry. “Looking ahead to 2026 and beyond, we anticipate export expansion into new regulated and semi-regulated markets, supported by expanded product portfolios, deeper regulatory engagement and strategic diversification,” Mehta said. GST Reboot Albeit the short term disruptions as reported in the Q2 earnings of players like Mankind and Glenmark, analysts anticipate a recovery in the coming quarters on higher patient base, as the move is expected to broaden access to a wider range of medicines. However, the higher duty—18 per cent— on inputs, continues to pose cash flow challenges for manufacturers and CDMOs, as stakeholders await a response on demands to include capital goods and services under the refund mechanism. According to experts, with innovation emerging as the defining force for the next phase of growth, in 2026, the emphasis will be on building scientific excellence and regulatory agility. The coming five years will be critical in translating policy momentum into measurable gains to achieve the industry's aspirational ambitions. By Online Bureau ,

Biosimilar

23 Dec 2025

·www.biospace.com

Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race

iStock, choi dongsu Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market. The FDA has approved Novo Nordisk’s Wegovy pill for weight management, making the product the first oral GLP-1 treatment for people who are overweight or have obesity in the U.S. Novo’s pill contains 25 mg of semaglutide, the GLP-1 receptor agonist found in the injectable version of Wegovy and its diabetes-indicated sibling Ozempic. The FDA approved the product based on data including a Phase III trial that linked the Wegovy pill to 16.6% mean weight loss. Patients lost similar amounts of weight on the once-daily oral and once-weekly injectable formulations of Wegovy. BMO Capital Markets analysts said in a note to investors that the approval is “a much-needed win in light of recent challenges maintaining incretin market share dominance.” Having initially led the GLP-1 market, Novo has lost ground amid competition from injectables sold by Eli Lilly and compounding pharmacies. The oral launch, which is set for early January, again establishes Novo as the first entrant to a potentially lucrative market. “Novo will likely benefit from first-mover advantage, capturing patients with a preference for convenience and comfort provided by an oral dosing regimen,” BMO analysts said. Yet Novo may have a short window in which to capitalize on its first-mover advantage. Lilly has filed for FDA approval of its oral GLP-1 candidate orforglipron and has a Commissioner’s National Priority Voucher that could accelerate regulatory review. Ilya Yuffa, president of Lilly USA, said at a Citi conference this month that the company expects to launch orforglipron early in the second quarter of 2026. GLP-1 A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover? August 13, 2025 · 5 min read · Nick Paul Taylor Read More This suggests Novo may have just a few months to establish a foothold in the oral GLP-1 market before facing competition. Average weight loss on orforglipron in a Phase III trial was 12.4%, compared to 13.7% on injectable Wegovy, according to results released in August. Lilly’s shares initially fell 7% in response to the data, although analysts have since become more bullish in their expectations for orforglipron. BMO analysts see orforglipron and other oral GLP-1 candidates as threats to the Wegovy pill. The analysts said the Wegovy pill’s food effect, which prevents patients from eating, drinking or taking other oral medications for 30 minutes after dosing, “is likely to limit uptake upon approval of orforglipron and other orals with more convenient pro ” The analysts expect investors to focus on Wegovy pill sales in 2026, “especially early in the launch when no true competition exists.” BMO’s team named data from a head-to-head trial of Novo’s CagriSema and Eli Lilly’s tirzepatide, the active ingredient in Mounjaro and Zepbound, expected in early 2026, as another focus of investor interest. Many investors expect Novo’s drug combination, which is under review at the FDA, to match tirzepatide, the analysts said. With noninferiority the baseline expectation, there is scope for perceptions of Novo to improve if CagriSema can beat tirzepatide. Yet BMO analysts said they are cautious because early CagriSema results have underperformed most expectations.

Phase 3Clinical ResultDrug Approval

22 Dec 2025

·www.einpresswire.com

Texas Court Dismisses Key Claims Against Compounding Pharmacy in Tirzepatide Dispute

PHA Chief Strategic Advisor Lee Rosebush, Esq. Helps Secure Important Legal Win for Personalized Medicine and Patient Access HOUSTON, TX, UNITED STATES, December 22, 2025 / EINPresswire.com / -- A Texas court has dismissed several claims against a compounding pharmacy in a high-profile legal dispute involving compounded tirzepatide, marking a significant development for patient access to individualized therapies and the lawful practice of pharmacy compounding. In Eli Lilly v. Revive Rx, LLC, Case No. 4:23-cv-03521 (S.D. Tex. Dec. 15, 2025), the court narrowed the scope of claims brought against Revive, reinforcing important legal principles governing compounding pharmacies and physician-directed care. The defense was led by Lee Rosebush, Esq., a nationally recognized healthcare attorney and Chief Strategic Advisor to the Personalized Health Association (PHA) The case centered on allegations related to compounded tirzepatide, a medication increasingly prescribed in personalized treatment protocols. By dismissing certain claims, the court clarified limits on liability and affirmed protections that allow clinicians and pharmacies to collaborate in providing tailored therapies when FDA-approved products may not adequately serve individual patients. Jimmy St. Louis, President of the Personalized Health Association, highlighted the broader implications of the ruling: “This ruling reinforces that personalized medicine depends on clear, workable legal frameworks,” said St. Louis. “When courts uphold lawful compounding, they help ensure patients can continue to access individualized therapies guided by physicians and grounded in safety and compliance.” Bill Moses, Founder of the Personalized Health Association, emphasized the policy significance of the decision: “This outcome highlights why modernized regulatory clarity is urgently needed,” Moses said. “Patients, physicians, and pharmacies all benefit when courts uphold lawful compounding as part of a personalized health ecosystem. Lee’s leadership in this case reflects the legal rigor and strategic insight required to protect patient access nationwide.” The decision arrives amid ongoing national debate over compounded medications, telemedicine, and the role of precision and regenerative therapies in addressing chronic disease. PHA views the ruling as an important signal that courts are willing to distinguish responsible compounding practices from inappropriate manufacturing claims. About the Personalized Health Association (PHA) The Personalized Health Association (PHA) is a national 501(c)(4) advocacy organization advancing safe, responsible access to regenerative and precision medicine. PHA leads federal and state efforts to modernize policies governing adult stem cell, peptide, and regenerative therapies, including advocating for updates to 21 C.F.R. §1271.10(a) to establish a clear, cGMP-based pathway for certain regenerative products to be regulated as 361 HCT/Ps. PHA represents healthcare providers, accredited regenerative-medicine facilities, compounding pharmacies, peptide-therapy providers, telemedicine platforms, and other healthcare stakeholders committed to high standards of safety, compliance, and evidence-based care. Through coordinated policy leadership, PHA champions physician autonomy and patient access to individualized therapies. Learn more at www.personalizedhealthassociation.org Candace McDonald Personalized Health Association +1 310-699-6311 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent Infringement

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	23 Dec 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Eli Lilly & Co.	23 Dec 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	26 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255433 (SURPASS-CVOT, Pubmed \| N Engl J Med)	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,174	Tirzepatide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)	sorbudjhxc(wulhiokyrz) = The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. lwgfiykrwq (dvevroyxvi ) View more	-	18 Dec 2025
				Dulaglutide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)
NCT05822830 (SURMOUNT-5, CTgov)	Phase 3	Obesity	751	Tirzepatide (15 mg or MTD - Tirzepatide)	kjfcyyeico(zinebujqmv) = gspksscaoo icfcffjcox (cgsvwrnjah, 0.59) View more	-	26 Nov 2025
				Semaglutide (2.4 mg or MTD - Semaglutide)	kjfcyyeico(zinebujqmv) = ayzoxskvuu icfcffjcox (cgsvwrnjah, 0.59) View more
NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	2,788	Tirzepatide	gaacokcaik(kaaxgqmhjd) = paoooxvvue bvwpzkyjpw (dufydrusuj ) View more	Positive	04 Nov 2025
NCT04657003 \| NCT05536804 \| NCT04184622 (SURMOUNT-1, Pubmed \| J Am Soc Nephrol)	Not Applicable	-	3,477	Tirzepatide	royewandsw(mjavznxmlt): Difference (%) = −55.2 (95.0% CI, −68.5 - −36.4) View more	Positive	01 Nov 2025
				Placebo
ACR2025	Not Applicable	Overweight \| Obesity	62,722	Tirzepatide	syzngmifzf(geqmkkfzll): HR = 0.88 (95.0% CI, 0.81 - 0.95) View more	Positive	24 Oct 2025
				Phentermine
NCT05963022 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	206	Tirzepatide (10 mg Tirzepatide)	fszjtoyalo(xcoohpvkbk) = xnopyniqit rabxhlqrea (yagexwolwh, 0.131) View more	-	21 Oct 2025
				Tirzepatide (15 mg Tirzepatide)	fszjtoyalo(xcoohpvkbk) = xmzzdjzrax rabxhlqrea (yagexwolwh, 0.124) View more
NCT06914141 \| NCT06914154 \| NCT06914102 (Pubmed \| JAMA)	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	pkxsnjjoqm(xrtnrxpdpe): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	14 Oct 2025
				Tirzepatide
NCT05260021 (SURPASS-PEDS, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	99	Mounjaro 5 mg	uuyuzxdmdp(ocsdjzjmvt) = hcxyyiipym mpqnqngqih (rkefoijvlo ) Met View more	Positive	17 Sep 2025
				Mounjaro 10 mg	uuyuzxdmdp(ocsdjzjmvt) = ttacmstild mpqnqngqih (rkefoijvlo ) Met View more
NCT05412004 (SURMOUNT-OSA, WSC2025 \| ATS2025)	Phase 3	Sleep Apnea, Obstructive	623	Tirzepatide	nevxfyekoy(bylvvujqgj): P-Value = 0.032 View more	Positive	05 Sep 2025
				Placebo
NCT05822830 (SURMOUNT-5, NEWS) Manual	Phase 3	Obesity	-	Tirzepatide	srgvffppbq(kpqrxrccat) = bmhklckxsq zmoecktfab (thhllkbjxx ) View more	Positive	01 Sep 2025
				Semaglutide	srgvffppbq(kpqrxrccat) = yoixyewvnk zmoecktfab (thhllkbjxx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis